-
-
-
-
-
-
-
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
-
-
-
-
-
-
-
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
-
-
-
-
-
-
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
-
-
-
-
-
-
-
Teva Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Teva Pharma (TEVA) Announces AUSTEDO XR Now Available in the U.S.
-
-
-
-
-
-
-
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
-
-
-
-
-
-
-
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
-
1,186,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

